“$ 1,5 billion have been spent on Medical Marijuana’s first DISPPension in May 2019.”
Sonny Albadado, according to Arkansas defenders
Arkansans spent Marihuana Medican more than 10 million, more than the first eight months of 2024, by placing a statue two years ago, according to the State Finance Department.
From January to August, Arkansans bought $ 193.1 million from the dolls of the State Medical marijuana, compared to $ 182.5 million last year, according to state financial and administrative state press release.
“We are on the road to overcoming the $ 283 million sales registration of $ 283 million in 2025,” Scott Scott said.
It has been an important growth in the number of pounds sold by the number of pounds sold, the hardship said, 2025 a total of 52,292 pounds.
The state gathered $ 5.38 million in medical marijuana tax entries in July and August, this year has been the total tax 21.57 million this year.
Patients spent 24,262,201 in July, buys 6,721 pounds and buys $ 24,647,170 in August, according to the financial department.
443 SUITE SPRINGS Hot Springs and Sherwood’s natural relief dispensibals sold the largest medical marijuana in July and August, according to the press release. Suite 443 sold 1,419.6 pounds for a total of two months. Natural relief sold 1,317.7 pounds in July and August.
“$ 1,5 billion have been spent since the first dyspension of the state Marijuana opened in May 2019,” Hardin said.
Arkansas Department Department Department 109,060 Active Patient Cards. The Marijuana Committee has 38 dispensares allowed, but only 36 are working, Hardin said. License of a last year’s authority has decided to drink Alcorage Control drink last year, and the appeal of his owner’s claim remains in front of the courts.
Greenhouse growers are working in conditions where crop yield and energy use must be managed simultaneously. According to Timo Spruijt, Chief Customer Officer at RED Horticulture, this requires a shift from fixed lighting schedules to approaches based on plant light responses.
“Lighting is moving from static control to measured and predictable strategies,” says Timo. “That starts with understanding how plants react to light and translating that into everyday decisions.”
This approach is based on photobiology, which links plant development to light conditions. Two parameters are central: intensity and spectrum. Light intensity affects photosynthesis, biomass accumulation and yield, while spectrum affects morphology, flowering, rooting and nutritional composition. Paul Vailhen, photobiologist at RED, points out that these factors must be managed together. “Focusing on one parameter without the other limits how plants use light. The interaction between intensity and spectrum determines photon efficiency.”
He explained that growers can use this knowledge to target harvests more precisely. “When photobiology is applied in practice, lighting becomes a management tool rather than a fixed input.”
Three areas To support this, RED Horticulture organizes its offer around three areas: luminaires, control platform and agronomic orientation. These components are intended to respond to changes during the day and during the cultivation phases. “The needs of the plants are not constant,” says Timo. “Lighting strategies must follow these variations.”
The MyRED platform is used to translate greenhouse data into lighting decisions. Growers can monitor performance and adjust lighting strategies through a dashboard. “The platform allows producers to define and modify their light recipes and evaluate the results,” explains Timo. “It links crop data with energy use.”
He added that implementation goes beyond software. “Support continues after installation. We work with growers to set goals, apply strategies and adjust over time.”
Energy use Energy use is a major factor in greenhouse operations. Timo connects lighting strategies directly with consumption. “Understanding how intensity and spectrum affect power use helps growers manage their energy input,” he says. “This could lead to changes in the way lighting is applied during the day.”
Automation is also part of today’s greenhouse practices. The system can adjust the lighting throughout the day according to predefined strategies. “Automation reduces manual adjustments and keeps light levels consistent,” says Timo. “It also allows control over the entire light output.”
He noted that automated control can contribute to additional energy savings beyond the performance of the luminaires. “When strategies are applied dynamically, further reductions in energy use are possible.”
Research This is another part of the research approach. Through the Photobiology and Agronomy Research Center (PARC), RED Horticulture conducts trials under controlled conditions. Timo explains how this relates to commercial production. “Trials allow strategies to be tested before implementation. Producers can then apply these results with a clearer view of expected outcomes.”
The goal is to make photobiology applicable to different crops and growing environments. “The same principles can be adapted to different varieties and production systems,” says Timo. It concludes by returning to the role of knowledge in greenhouse management. “Understanding photobiology is the starting point. From there, growers can build lighting strategies that match crop requirements and energy constraints.”
For more information: RED Horticulture World Horti Center Europe 1 2672 ZX Naaldwijk +31 174 705 617 horticulture.red/
The House Finance Committee advanced the legislation to Sen. Chris Lee (D) on a 15-0 vote Tuesday. The measure, which passed the Senate last month by a 24-0 vote, will next go to the House floor before returning to the Senate for that chamber to consider final amendments.
The bill would create Creative Mental Health Therapy, a two-year review of the current scientific literature, supporting additional clinical research and developing policy recommendations for the “safe, ethical, and culturally informed implementation” of a psychedelic therapy program.
“The Legislature believes in addressing the mental health crisis affecting the State’s residents, particularly among veterans, first responders and trauma survivors,” SB 3199 reads. “Suicide remains the leading cause of preventable death, and the State must explore all safe and effective treatment options supported by scientific evidence.”
Given that the Federal Food and Drug Administration (FDA) has designated psilocybin and MDMA as breakthrough therapies in the treatment of serious mental health conditions, which may be subject to future control under the Controlled Substances Act (CSA), Hawaii’s legislation states that the state must “proactively prepare public health, clinical and research systems for safe and equitable implementation.”
The state Department of Health said in House committee testimony that it supports the bill, noting that in light of the FDA’s action on psychedelics, it is “prudent for Hawaii to assess research readiness, regulatory implications, workforce development and culturally informed implementation pathways” before any federal rescheduling of the substances.
The Governor’s Office of Wellness and Resiliency said the bill “has an important opportunity to begin paving a planned pathway for people who need access to life-saving treatments for trauma and other mental health issues.”
“A growing body of research demonstrates that breakthrough therapies (such as MDMA and psilocybin-assisted therapies) demonstrate high efficacy and positive clinical outcomes in the treatment of post-traumatic stress disorder, substance use disorders, end-of-life anxiety, eating disorders, depression, treatment-resistant, and additional conditions in terminally ill patients.”
Team members should include representatives from the State Department of Health (DOH), the Office of the Attorney General, the Office of Wellness and Resiliency (OWR), the University of Hawaii School of Medicine, and more.
Like the draft, the DOH would oversee the task force, an amendment approved by the House Health Committee last month makes the University of Hawaii John A. Burns School of Medicine (JABSOM) the responsible institution, and JABSOM’s nominee as the panel’s chairman.
The commission also adopted amendments suggested by the Department of Law Enforcement to say that its Division of Narcotics Enforcement — and not the Board of Pharmacy — would be responsible for changing the state’s scheduling of psychedelics after any federal reclassification, and to change the deadline for doing so from 90 days to 30 days.
Members note in their bill report that the state Agency for Health Planning and Development has expressed concern that psychedelics are illegal under federal law and that the task force should proceed with caution.
Finally, the panel made technical corrections for clarity, consistency, and style.
A separate marijuana legalization bill, SB 2421, that contained provisions under federal reform law or amendments to the state Constitution, was delayed for action. The Senate and House panels also delayed action on a measure to sell certain hemp-derived cannabinoid products.
A Senate committee also adopted the resolutions Asking Congress to federally legalize marijuanasupport the state’s efforts to clean up people’s criminal records and take steps to make it easier for cannabis companies to access banking services.
Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.
The Drug Enforcement Administration (DEA) says the marijuana redistricting appeals process “remains pending” despite President Donald Trump issuing an executive order more than three months ago ordering the attorney general to pursue reform “as expeditiously as possible.”
The DEA and reform advocates filed a joint status report Monday on the agency’s interlocutory appeal of bias and improper communications with parties opposed to the redistricting.
“To date, the Movants’ interlocutory appeal to the Administrator on the Motion for Reconsideration remains pending with the Administrator,” said attorneys representing the DEA and cannabis reform advocates who are challenging the process. “No information schedule has been established.”
The agency is responsible for establishing the information schedule. But nearly a year after a former administrative law judge granted the appeal, the DEA is once again delaying the process. This is the fifth consolidated status report, with largely identical language, that the parties have submitted under the administrative litigation order.